Veru Q2 2024 Adj EPS $(0.07) Misses $(0.05) Estimate, Sales $4.10M Beat $3.00M Estimate

5/8/24 6:33:16 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VERU alert in real time by email

Veru (NASDAQ:VERU) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. The company reported quarterly sales of $4.10 million which beat the analyst consensus estimate of $3.00 million by 36.67 percent. This is a 37.75 percent decrease over sales of $6.59 million the same period last year.

Get the next $VERU alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VERU

Date	Price Target	Rating	Analyst
5/14/2024	$5.00	Buy	B. Riley Securities
3/28/2024	$3.00	Outperform	Raymond James
6/7/2023	$1.00	Underperform → Hold	Jefferies

More analyst ratings

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
MIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas. Highlights from the presentation:The objective of the meta-analysis was to determine the effects of enobosarm on body composition in older patients that had obesity who were enrolled in 4 previously conducted randomized clinical trials of enobosarm that measured body composition including
11/5/24 8:30:00 AM ET
$VERU
Biotechnology: Pharmaceutical Preparations
Health Care
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
MIAMI, FL, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at ObesityWeek, taking place November 3-6, 2024, in San Antonio, Texas. Presentation Name: Meta-analysis of subjects from 4 randomized clinical trials supports the potential of enobosarm to optimize weight lossDate: November 5, 2024Start and end time: 2:30 PM – 3:30 PM Central Daylight TimeLocation: Henry B. González Convention Center, San Antonio, TX Additional informa
10/21/24 8:30:00 AM ET
$VERU
Biotechnology: Pharmaceutical Preparations
Health Care
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at the World Obesity and Weight Management Congress, taking place October 24-26, 2024, in Baltimore, Maryland. Keynote Presentation Name: Advancing enobosarm, an oral novel Selective Androgen Receptor Modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) drugs for potentially higher quality we
10/16/24 8:30:00 AM ET
$VERU
Biotechnology: Pharmaceutical Preparations
Health Care

$VERU
Financials

Live finance-specific insights

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
--Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected January 2025-- --Company presented enobosarm for high quality weight loss at the American Diabetes Association Meeting, the American Association of Clinical Endocrinology Annual Meeting, Biomed Israel 2024, and the GLP-1 Based Therapeutics Summit-- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving mus
8/8/24 6:30:00 AM ET
$VERU
Biotechnology: Pharmaceutical Preparations
Health Care
Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Thursday, August 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 third quarter financial results and to provide a business update. The audio webcast will be accessible under the Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (inte
8/1/24 8:30:00 AM ET
$VERU
Biotechnology: Pharmaceutical Preparations
Health Care
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical, clinical and scientific expertise-- --Company to present this month at upcoming American Association of Clinical Endocrinology annual meeting and GLP-1 Based Therapeutics Summit-- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, May 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle f
5/8/24 6:30:00 AM ET
$VERU
Biotechnology: Pharmaceutical Preparations
Health Care

$VERU
Leadership Updates

Live Leadership Updates

Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board
MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of Erik Swenson, M.D., a world-renowned pulmonologist specializing in critical care, and Robert Schooley, M.D., an accomplished infectious disease physician and researcher, to its Infectious Disease Scientific Advisory Board (SAB) to join David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, who is Chairman of the SAB. "We are pleased to share that Dr. Erik Swenson and
6/1/23 8:30:00 AM ET
$VERU
Biotechnology: Pharmaceutical Preparations
Health Care
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB). "Today's appointment of Dr. Ho as Chairman of Veru's SAB illustrates our commitment to building a team of scientific experts to support our goal of developing and delivering life-saving therapies to patients with COVID-19 and other viral ARDS-related diseases," said Mitchell Steiner, M.D., Chairman, Presi
1/10/23 8:30:00 AM ET
$VERU
Biotechnology: Pharmaceutical Preparations
Health Care
Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients
MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Jason Davies as Executive Vice President – General Manager of Europe, the Middle East and Africa (EMEA), Latin America (LATAM), and Asia Pacific (APAC) for Veru's Infectious Disease Franchise for Veru International. Most recently Mr. Davies had been the EMEA Head of Launch Excellence – Pharmaceutical Portfolio at Janssen (Johnson & Johnson) where he was responsible for creating and leading a new organization to enhan
8/19/22 8:30:00 AM ET
$VERU
Biotechnology: Pharmaceutical Preparations
Health Care

$VERU
Market Insights

Live Market Insights

Veru Presents Phase 2 and 3 Enobosarm Data At ADA Scientific Sessions: Well-Tolerated With Comparable Adverse Event Profile To Placebo; Effective In Reducing Fat And Preserving Lean Mass In Older Adults And Cancer Patients
6/24/24 8:39:14 AM ET
$VERU
Biotechnology: Pharmaceutical Preparations
Health Care
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter financial results. Bank of Montreal posted quarterly adjusted earnings of C$2.59 per share, missing market estimates of C$2.77 per share. The company's quarterly sales came in at C$7.988 billion missing expectations of C$8.046 billion, according to data from Benzinga Pro. Bank of Montreal shares declined 7.1% to $89.32 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers ReShape Lifesciences Inc. (NASDAQ:RSLS) shares jumped 82.8% to $0.3799 a day after it received the nod from the U.S. Patent And Trademark O
5/29/24 1:28:35 PM ET
$AAL
$AAP
$ANF
$ASTI
Air Freight/Delivery Services
Consumer Discretionary
Auto & Home Supply Stores
Clothing/Shoe/Accessory Stores
Comstock And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed lower by over 200 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Comstock The Trade: Comstock Inc. (NYSE:LODE) Chief Engineering Officer Rahul Bobbili bought a total of 25,000 shares at an average price of $0.25. To acquire these shares, it cost around $6,350. What's Happening: Comstock, on May 17, announced
5/29/24 8:34:11 AM ET
$LODE
$VERU
Major Chemicals
Industrials
Biotechnology: Pharmaceutical Preparations
Health Care

Veru Q2 2024 Adj EPS $(0.07) Misses $(0.05) Estimate, Sales $4.10M Beat $3.00M Estimate

Chat with this insight

Recent Analyst Ratings for $VERU

$VERU SEC Filings

SEC Form 8-K filed by Veru Inc.

SEC Form 8-K filed by Veru Inc.

SEC Form 8-K filed by Veru Inc.

$VERU Press Releases

Fastest customizable press release news feed in the world

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

$VERU Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Fisch Harry bought $5,000 worth of shares (4,000 units at $1.25), increasing direct ownership by 0.52% to 774,736 units (SEC Form 4)

Barnette K Gary bought $6,696 worth of shares (5,000 units at $1.34) (SEC Form 4)

Fisch Harry bought $9,999 worth of shares (6,711 units at $1.49), increasing direct ownership by 0.88% to 770,736 units (SEC Form 4)

$VERU Financials

Live finance-specific insights

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

$VERU Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

B. Riley Securities initiated coverage on Veru with a new price target

Raymond James initiated coverage on Veru with a new price target

Veru upgraded by Jefferies with a new price target

$VERU Leadership Updates

Live Leadership Updates

Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients

$VERU FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for ENTADFI issued to VERU INC

$VERU Market Insights

Live Market Insights

Veru Presents Phase 2 and 3 Enobosarm Data At ADA Scientific Sessions: Well-Tolerated With Comparable Adverse Event Profile To Placebo; Effective In Reducing Fat And Preserving Lean Mass In Older Adults And Cancer Patients

Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Comstock And 2 Other Stocks Under $2 Insiders Are Buying

$VERU Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Hyun Grace

SEC Form 4 filed by Director Rankowitz Michael L

SEC Form 4 filed by Director Lu Lucy

$VERU Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Veru Inc.

Amendment: SEC Form SC 13G/A filed by Veru Inc.

SEC Form SC 13G filed by Veru Inc.

Recent Analyst Ratings for
$VERU

$VERU
SEC Filings

$VERU
Press Releases

$VERU
Insider Purchases

$VERU
Financials

$VERU
Analyst Ratings

$VERU
Leadership Updates

$VERU
FDA approvals

$VERU
Market Insights

$VERU
Insider Trading

$VERU
Large Ownership Changes